PROTAC BRD4 Degrader-13 is primarily used in biomedical research to study and target the BRD4 protein, which plays a critical role in gene regulation and cancer progression. Its application is focused on degrading BRD4 through the ubiquitin-proteasome system, offering a novel approach to understanding and potentially treating diseases where BRD4 is overexpressed, such as certain cancers. Researchers utilize this compound to explore targeted protein degradation as a therapeutic strategy, particularly in preclinical studies for oncology. It serves as a valuable tool for investigating the mechanisms of BRD4 in cellular processes and evaluating the efficacy of PROTAC technology in drug development.